scispace - formally typeset
Open AccessJournal ArticleDOI

National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management.

TLDR
Recommendations for the management of COVID-19 patients are shown, based on very limited clinical evidences, which should be considered as expert opinions, which may be modified according to newly produced literature data.
Abstract
On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The "L. Spallanzani" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Drug repurposing approach to fight COVID-19.

TL;DR: The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective.
Journal ArticleDOI

The neurological manifestations of COVID-19: a review article.

TL;DR: Various evidences support the possible CNS roles in the COVID-19 pathophysiology and further investigation of CNS involvement of SARS-COV-2 is suggested.
Journal ArticleDOI

COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?

TL;DR: This review analyzes the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and underline the similarities between this condition and “hyperferritinemic syndromes” which would allow considering this entity as the fifth member of the spectrum of inflammatory conditions.
Journal ArticleDOI

COVID-19 and the clinical hematology laboratory.

TL;DR: The laboratory's role in the diagnosis of COVID‐19 infection is discussed, the current state of biomarker analysis in COVID'S infection is summarized, and the impact of the pandemic has had on organized national and international educational activities worldwide is described.
Journal ArticleDOI

Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis.

TL;DR: The prevalence of symptomatic COVID-19 was found to be higher in men than in women, and the high prevalence of smoking and alcohol consumption contributed to thehigh prevalence of CO VID-19 among men.
References
More filters
Journal ArticleDOI

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI

Acute respiratory distress syndrome: the Berlin Definition.

TL;DR: The updated and revised Berlin Definition for ARDS addresses a number of the limitations of the AECC definition and may serve as a model to create more accurate, evidence-based, critical illness syndrome definitions and to better inform clinical care, research, and health services planning.
Journal ArticleDOI

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Related Papers (5)